BioAtla Inc (BCAB) Q4 2024 Earnings Report

BioAtla reported a materially non-revenue quarter in Q4 2024 with a substantial R&D and operating expense base, yet notable year-over-year improvement in profitability metrics as the company consolidates programs and tightens resources. Net loss for the quarter was -$14.9 million, an improvement from -$26.9 million in the prior-year period, reflecting a meaningful reduction in operating expenses (R&D down to $11.6 million and G&A down to $4.6 million) as the company prioritizes its most promising CAB-based assets. Full-year cash burn moderated to -$72.0 million versus -$104.0 million in 2023, but ending cash and equivalents stood at $49.0 million, underscoring a working capital runway challenge that BioAtla is actively addressing through a targeted workforce realignment (>30% headcount reduction) and a focus on two internal priority programs.

Management emphasized the differentiated clinical profile of its CAB platform across multiple assets, supported by early readouts and encouraging durability signals. The EpCAM T-cell engager program (BA3182) is in dose escalation with a planned mid-2025 readout for the dose-escalation portion and a first-half 2026 readout for cohort expansion; the team believes the therapeutic window can be widened with target doses around 200 micrograms and above. Mec-V (CAB-AXL-ADC) demonstrated compelling overall survival signals in MKRAS-mutant NSCLC with 66% and 58% of patients alive at 1 and 2 years in the 1.8 mg/kg Q2W cohort, and a safety profile with a drug-related discontinuation rate of 7%. HPV-positive head and neck cancer data for Oz-V (R2-ADC) showed a complete response in at least one patient and a 100% disease control rate in the HPV-positive subgroup, alongside a 45% objective response rate and ongoing responses beyond 5 months. Evalstotug (CAB CTLA-4) in combination with PD-1 achieved an overall response rate of 64% and disease control of 100% across 11 evaluable patients, signaling potential best-in-class activity in a comparably differentiated safety profile.

Looking ahead, BioAtla is pursuing corporate partnerships to monetize its Phase 2 assets while extending runway into mid-2026 and beyond. Management outlined that strategic discussions are underway for EpCAM, Oz-V, ROR2, and CTLA-4, with ongoing collaboration dialogues expected to accelerate post-data readouts. The near-term catalysts include mid-2025 EpCAM dose-escalation data, 1H2026 EpCAM expansion data, and continued updates from Oz-V and Mec-V presentations. The company’s objective to align with partners that can maximize value—especially for high-potential subpopulations such as HPV+ HNC and MKRAS-driven NSCLC—constitutes a core element of BioAtla’s near-to-medium-term investment thesis.